Oklahoma Lawmaker: Stop Rewriting Medical Marijuana Rules

October 14, 2026

Photo by Stan Paregien Sr via Unsplash.

Eight years after Oklahoma voters legalized medical marijuana with State Question 788, the rulebook governing the industry still hasn't stopped moving. On October 13, 2026, lawmakers gathered at the Capitol for a House interim study meant to take stock of that churn, and the chairman overseeing cannabis policy used the moment to make a blunt request: stop changing the rules so often. Rep. T.J. Marti, R-Broken Arrow, who chairs the House Alcohol, Tobacco and Controlled Substances Committee, told colleagues it's time to let recently passed laws actually play out before the state piles on more regulation.

The irony of the hearing is that it didn't exactly cooperate with his message. Even as Marti argued for a pause, a parade of witnesses -- patients, lab operators, industry advocates and regulators -- showed up with more than a dozen new ideas for how Oklahoma should police its medical cannabis market. That split captures the real tension running through Oklahoma cannabis policy right now: an industry and regulatory agency worn down by near-constant rule changes, set against genuine, unresolved problems -- chief among them, a lab testing system that a growing number of patients and operators simply don't trust.

A Chairman Says Enough Is Enough

Marti isn't a bystander complaining about rules somebody else wrote. As chair of the House committee with direct jurisdiction over marijuana policy, he's personally authored several of the regulatory bills that have reshaped Oklahoma's medical market in recent years. That makes his call for restraint carry a bit more weight than if it came from an outside critic -- he's asking the Legislature to pump the brakes on a process he's actively helped drive.

His argument at the October hearing was straightforward: let's see what shakes out from the things we've done in the first six years, give the industry a break and time to show if changes were beneficial. It's worth sitting with that phrasing, because it's not an anti-regulation stance. Marti isn't arguing Oklahoma over-regulated its medical marijuana program. He's arguing that the state has changed the rules so frequently that nobody -- not regulators, not growers, not testing labs -- can actually tell whether any particular fix worked before the next one lands on top of it.

The numbers back up his frustration. Since SQ 788 passed in 2018, the Oklahoma Medical Marijuana Authority's rules have shifted almost annually, forcing growers, processors, dispensaries and labs to continually revise compliance procedures, paperwork and operating practices. The most recent round of emergency rules took effect August 28, 2026, implementing HB3143, which extends the state's business license moratorium out to August 2028. That's a significant, multi-year commitment -- and Marti's point is that measures like it deserve enough runway to actually generate usable data before lawmakers decide whether to tweak them again.

Then Came a Dozen New Proposals Anyway

Photo by jarmoluk via Pixabay.

Rep. Jacob Rosecrants, D-Norman, hosted the October 13 study, and the witness list he assembled told its own story. Patients testified about their experiences navigating the medical program. Industry advocates and testing lab representatives weighed in on compliance burdens. OMMA staff fielded questions about agency capacity. By the end of the day, more than a dozen distinct regulatory proposals had been floated -- and nearly all of them circled back to one theme: mistrust in cannabis testing and product safety.

Rosecrants used his platform to push a specific set of priorities. He argued Oklahoma needs to expand its lab capabilities so testing can reliably catch pesticides and other hazardous substances in medical marijuana products -- not just confirm potency numbers. He also urged lawmakers to start preparing now for the possibility of federal marijuana reclassification, a shift that could upend state-level compliance structures regardless of what Oklahoma decides to do on its own timeline.

What gave his testimony particular weight was a personal account: Rosecrants described being sickened by a contaminated cannabis product himself. That's not an abstract policy concern for him -- it's the reason he keeps pushing for more oversight even while acknowledging that the industry is tired of constant rule changes. It's a useful illustration of why reform fatigue and reform urgency are showing up in the same room, sometimes in the same lawmaker. Nobody at the hearing disputed that compliance costs are real; the disagreement is over whether the state has actually closed its safety gaps yet, or just changed the paperwork around them.

The Testing Trust Problem Behind the Push

In Oklahoma, a share of patients say they trust the accuracy of lab testing for medical marijuana, while others remain skeptical—highlighting a notable trust gap that could be impacted by frequent regulatory changes.

The testing issue isn't just anecdotal. Researcher Marion McNabb cited a recent report finding that roughly 30% of surveyed Oklahoma medical marijuana patients distrust the accuracy of lab testing results tied to the products they're buying. That's not a fringe number -- it points to a credibility problem touching close to a third of the patient base the program exists to serve.

Gillian Schauer, representing the Cannabis Regulators Association, zeroed in on a structural reason why. Oklahoma relies on an end-of-process testing model, meaning labs test finished products rather than sampling throughout cultivation and production. Schauer's concern was pointed: labs face pressure to falsify results because failing a batch at that late stage means the grower or processor loses the entire inventory, not just a portion of it. When the financial stakes of a failed test are that severe, the incentive structure can push labs toward leniency rather than rigor -- a dynamic regulators in other states have also grappled with.

OMMA's chief administrative officer, Barret Brown, offered a partial response to these concerns, telling lawmakers the agency's own quality assurance lab is now operational. But he acknowledged it's still awaiting accreditation for certain testing capabilities, meaning the state's backstop against bad lab results isn't yet fully up and running. That gap matters. It's the kind of concrete, unresolved problem that explains why even lawmakers sympathetic to Marti's call for a pause keep finding themselves unable to simply freeze the rulebook -- testing integrity is the one area where the case for more action, not less, is hardest to wave away.

A Pattern of Churn Since 2018

Photo via Pexels.

Oklahoma's medical marijuana program exists because voters approved SQ 788 in 2018, and it remains the only legal cannabis framework in the state after voters rejected adult-use legalization under SQ 820 in 2023. That history matters for context: Oklahoma never built a recreational market to absorb some of this regulatory pressure, so every fix, loophole and patch gets layered onto the medical system alone.

The 2026 legislative session alone produced a notable stack of marijuana-related bills: HB3143 extending the business license moratorium, HB3144 capping the number of licensed growers, HB3127 addressing employer provisions around medical marijuana use, HB2837 mandating new training requirements, and SB786 aligning open-container rules with existing alcohol law. That's five separate pieces of legislation touching distinct corners of the industry in a single session -- exactly the kind of volume Marti was referencing when he asked colleagues to let things settle.

A smaller episode from just days before the hearing underscored the point. On October 8, 2026, OMMA had to publicly clarify that a lab email mistakenly distributed to industry contacts -- discussing flavoring and coloring ingredients -- wasn't actually a new rule at all. The agency apologized for the confusion it caused. It's a minor incident in isolation, but it became something of a case study in why operators feel constant whiplash: when the regulatory environment changes so often, even a miscommunication that isn't a rule change can look and feel like one. Readers should keep in mind that cannabis law varies considerably by state, and Oklahoma's medical-only structure operates under rules distinct from those in recreational markets -- anyone making business or compliance decisions should confirm current OMMA requirements directly rather than relying on summaries of past policy.

Strip away the back-and-forth at the October hearing, and the actual disagreement isn't deregulation versus regulation. Nobody at the Capitol argued Oklahoma should walk away from oversight of its medical marijuana market. The real fight is about sequencing -- whether the state lets HB3143's extended moratorium, the new training mandates and recent lab rules actually run their course before legislators layer on another round of changes on top of them.

That debate may end up being overtaken by events outside Oklahoma's control. If federal marijuana reclassification moves forward, it will likely force the state's hand regardless of what lawmakers in Oklahoma City decide to pause or pursue on their own timeline. A rescheduling decision would ripple into banking, testing standards and interstate commerce questions that no amount of legislative restraint at the state level can fully insulate against.

In the meantime, expect the lab testing trust problem to keep resurfacing as the one issue even pause-minded legislators can't quite leave alone. A 30% patient distrust rate and an accreditation gap at OMMA's own quality assurance lab aren't the kind of numbers that invite a wait-and-see approach. Marti's instinct to let the dust settle makes sense for licensing caps and employer rules, where the data genuinely needs time to accumulate. Testing integrity looks like the exception -- the one corner of Oklahoma's medical marijuana program where doing nothing for another year may carry more risk than doing something imperfectly right now.